Literature DB >> 19279015

Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis.

Y Allanore1, C Meune, M C Vonk, P Airo, E Hachulla, P Caramaschi, G Riemekasten, F Cozzi, L Beretta, C T Derk, A Komócsi, D Farge, A Balbir, V Riccieri, O Distler, A Chialà, N Del Papa, K Pasalic Simic, M Ghio, B Stamenkovic, S Rednic, N Host, R Pellerito, E Zegers, A Kahan, U A Walker, M Matucci-Cerinic.   

Abstract

OBJECTIVES: To measure the prevalence of, and factors associated with, left ventricular (LV) dysfunction in systemic sclerosis (SSc).
METHODS: The EUSTAR database was first searched. A case-control study of a patient subset was then performed to further identify independent factors associated with LV dysfunction by simple and multiple regression.
RESULTS: Of 7073 patients, 383 (5.4%) had an LV ejection fraction (EF) of <55%. By multiple regression analysis, age, sex, diffuse cutaneous disease, disease duration, digital ulcerations, renal and muscle involvement, disease activity score, pulmonary fibrosis and pulmonary arterial hypertension were associated with LV dysfunction. In the second phase, 129 patients with SSc with LVEF <55% were compared with 256 patients with SSc with normal LVEF. Male sex (OR 3.48; 95% CI 1.74 to 6.98), age (OR 1.03; 95% CI 1.01 to 1.06), digital ulcerations (OR 1.91; 95% CI 1.05 to 3.50), myositis (OR 2.88; 95% CI 1.15 to 7.19) and use of calcium channel blockers (OR 0.41; 95% CI 0.22 to 0.74) were independent factors associated with LV dysfunction.
CONCLUSION: The prevalence of LV dysfunction in SSc is 5.4%. Age, male gender, digital ulcerations, myositis and lung involvement are independently associated with an increased prevalence of LV dysfunction. Conversely, the use of calcium channel blockers may be protective.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19279015     DOI: 10.1136/ard.2008.103382

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  55 in total

Review 1.  N-TproBNP as biomarker in systemic sclerosis.

Authors:  Tommaso Schioppo; Carolina Artusi; Teresa Ciavarella; Francesca Ingegnoli; Antonella Murgo; Silvana Zeni; Cecilia Chighizola; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 2.  Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis.

Authors:  Theodoros Dimitroulas; Sophie Mavrogeni; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2012-02-07       Impact factor: 20.543

3.  Left ventricular systolic dysfunction in two patients with ankylosing spondylitis: What is the role of corticosteroids?

Authors:  Ahmad Amin; Mitra Chitsazan; Hossein Navid
Journal:  Eur J Rheumatol       Date:  2016-04-05

Review 4.  Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis.

Authors:  Hiroshi Satoh; Makoto Sano; Kenichiro Suwa; Takeji Saitoh; Mamoru Nobuhara; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  World J Cardiol       Date:  2014-07-26

5.  Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis.

Authors:  Raluca B Dumitru; Lesley-Anne Bissell; Bara Erhayiem; Graham Fent; Ananth Kidambi; Peter Swoboda; Giuseppina Abignano; Helena Donica; Agata Burska; John P Greenwood; John Biglands; Francesco Del Galdo; Sven Plein; Maya H Buch
Journal:  Rheumatology (Oxford)       Date:  2021-06-18       Impact factor: 7.580

6.  Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.

Authors:  Matthew R Lammi; Lesley A Saketkoo; Jessica K Gordon; Paula Lauto; Karen Fagan; Virginia D Steen
Journal:  Respirology       Date:  2017-05-12       Impact factor: 6.424

Review 7.  Is there evidence for vasculitis in systemic sclerosis?

Authors:  Lesley Ann Saketkoo; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 8.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

Review 9.  A critical view on cardiovascular risk in systemic sclerosis.

Authors:  Antonios Psarras; Stergios Soulaidopoulos; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2016-07-12       Impact factor: 2.631

Review 10.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.